Following “promising trials,” a drugs company from Cambridge, Massachusetts, has claimed that medicine that might slow down Alzheimer’s could be released soon.
Biotechnology giant Biogen has announced the good news after years of failed dementia treatment trials around the world.
Now, the company has claimed it has come across “transformative discovery” in their “promising trials” and suggested that the groundbreaking drug could change the lives of Alzheimer’s patients for the better.
According to Biogen, the data they obtained from their trials confirms that drug aducanumab is potent enough to counter the effects of the disease and go into production across the globe.
As the company claimed, the results of their trial show that the drug helped improve the condition of over 3,000 Alzheimer’s sufferers.
“We got clear support from the FDA. With such a devastating disease that affects tens of millions worldwide, today’s announcement is truly heartening in the fight against Alzheimer’s,” CEO Michel Vounatsos said.
As they added, the revolutionary drug should be available to everyone in two years. Following these claims, the company saw a drastic, 35% rise in the value of their shares.
The news of the alleged breakthrough follows just months after Biogen announced their previous trials involving the same drug had been unsuccessful.
While the experts around the world have praised the company for its breakthrough in medicine, some have urged the public not to get their hopes up until Biogen fully releases their results.
“After the trial being stopped earlier this year because it appeared not to work, further analysis suggests that it does benefit people with dementia in the earliest stages,” Dr. James Pickett of the Alzheimer’s Society expressed.
“We’re waiting for further data but this could be the first new treatment for Alzheimer’s disease in over 15 years, and as such, has the potential to be a transformative discovery.”
On the other side of the table, calling for caution was Professor Rob Howard of the University College London who said:
“We have been down this road before. We are only being allowed to see a cherry-picked selection of data and I suspect once we see the full results we will see that the clinical effect is very small indeed.”
What are your thoughts on this story? Let us know in the comments and don’t forget to SHARE this post with your family and friends and follow us on Facebook for more news and stories!
Replaced!